NCT07249905 2026-03-03
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
ModeX Therapeutics, An OPKO Health Company
Stanford University
Poseida Therapeutics, Inc.